Vertex Pharmaceuticals Inc (NAS:VRTX)
$ 422.78 3.79 (0.9%) Market Cap: 109.10 Bil Enterprise Value: 99.65 Bil PE Ratio: 27.44 PB Ratio: 5.89 GF Score: 94/100

Q2 2019 Vertex Pharmaceuticals Inc Earnings Call Transcript

Jul 31, 2019 / 08:30PM GMT
Release Date Price: $166.62 (-1.72%)
Michael Partridge
Vertex Pharmaceuticals Incorporated - SVP of IR

Welcome. This is Michael Partridge, Senior Vice President of Investor Relations. Tonight, we will review with you Vertex's business progress and provide our second quarter financial results.

Making prepared remarks on the call tonight, we have Dr. Jeff Leiden, Chairman and CEO; Dr. Reshma Kewalramani, Chief Medical Officer; and Charlie Wagner, Vertex's Chief Financial Officer. Stuart Arbuckle, Chief Commercial Officer, will join us for Q&A. We recommend that you access the webcast slides on our website as you listen to the call. This conference call is being recorded and a replay will be on our website.

We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and our filings with the Securities and Exchange Commission. These statements, including, without limitation, those regarding Vertex's marketed CF medicines, the ongoing development and potential commercialization of our triple combination regimens for cystic fibrosis,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot